%0 Journal Article
%T Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy
%A Christoph Oehler-J£¿nne
%A Burkhardt Seifert
%A Urs M L¨¹tolf
%A I Frank Ciernik
%J Radiation Oncology
%D 2006
%I BioMed Central
%R 10.1186/1748-717x-1-29
%X Clinical outcome of 81 HIV-seronegative patients (1988 ¨C 2003) and 10 consecutive HIV-seropositive patients under HAART (1997 ¨C 2003) that were treated with 3-D conformal RT of 59.4 Gy and standard 5-fluorouracil and mitomycin-C were retrospectively analysed. 10 TNM-stage and age matched HIV-seronegative patients (1992 ¨C 2003) were compared with the 10 HIV-seropositive patients. Pattern of care, local disease control (LC), overall survival (OS), cancer-specific survival (CSS), and toxicity were assessed.RT with or without CT resulted in complete response in 100 % of HIV-seropositive patients. LC was impaired compared to matched HIV-seronegative patients after a median follow-up of 44 months (p = 0.03). OS at 5 years was 70 % in HIV-seropositive patients receiving HAART and 69 % in the matched controls. Colostomy-free survival was 70 % (HIV+) and 100 % (matched HIV-) and 78 % (all HIV-). No HIV-seropositive patient received an interstitial brachytherapy boost compared to 42 % of all HIV-seronegative patients and adherence to chemotherapy seemed to be difficult in HIV-seropositive patients. Acute hematological toxicity reaching 50 % was high in HIV-seropositive patients receiving MMC compared with 0 % in matched HIV-seronegative patients (p = 0.05) or 12 % in all HIV-seronegative patients. The rate of long-term side effects was low in HIV-seropositive patients.Despite high response rates to organ preserving treatment with RT with or without CT, local tumor failure seems to be high in HIV-positive patients receiving HAART. HIV-seropositive patients are subject to treatment bias, being less likely treated with interstitial brachytherapy boost probably due to HIV-infection, and they are at risk to receive less chemotherapy.The incidence of cancer of the anal canal is rising due to the increasing prevalence of HIV-infection and HPV-infection [1-4]. Standard therapy for invasive anal cancer is radiotherapy (RT) or chemo-radiation resulting in local tumor control (LC) rates
%U http://www.ro-journal.com/content/1/1/29